share_log

Tracon Pharmaceuticals | EFFECT: Others

Tracon Pharmaceuticals | EFFECT: Others

Tracon Pharmaceuticals | EFFECT:其他
美股SEC公告 ·  11/04 06:05

Moomoo AI 已提取核心訊息

Tracon Pharmaceuticals, Inc. has achieved a significant regulatory milestone with the United States Securities and Exchange Commission (SEC) declaring a Notice of Effectiveness on November 1, 2024. The document, bearing the Accession Number 0000950170-24-119574, was submitted under the type POS AM, indicating an amended post-effective amendment. This notice marks a key step for Tracon Pharmaceuticals, allowing the company to proceed with actions that were contingent on the SEC's approval.
Tracon Pharmaceuticals, Inc. has achieved a significant regulatory milestone with the United States Securities and Exchange Commission (SEC) declaring a Notice of Effectiveness on November 1, 2024. The document, bearing the Accession Number 0000950170-24-119574, was submitted under the type POS AM, indicating an amended post-effective amendment. This notice marks a key step for Tracon Pharmaceuticals, allowing the company to proceed with actions that were contingent on the SEC's approval.
tracon pharmaceuticals公司已經在2024年11月1日取得了與美國證券交易委員會(SEC)達成的重要監管里程碑,宣佈生效通知。該文件編號爲0000950170-24-119574,提交類型爲pos Am,表明修訂後的後期生效修正。此通知標誌着Tracon Pharmaceuticals邁出的關鍵一步,使公司能夠繼續進行取決於SEC批准的行動。
tracon pharmaceuticals公司已經在2024年11月1日取得了與美國證券交易委員會(SEC)達成的重要監管里程碑,宣佈生效通知。該文件編號爲0000950170-24-119574,提交類型爲pos Am,表明修訂後的後期生效修正。此通知標誌着Tracon Pharmaceuticals邁出的關鍵一步,使公司能夠繼續進行取決於SEC批准的行動。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息